ResearcherCleveland ClinicNo recent work listed

Yogen Saunthararajah

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9757-1031; OpenAlex author ID A5049987484; NIH RePORTER profile ID 8410099. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 1
Labs led: 1
Collaborators: 4

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: 1 grant

Papers 1

A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic c… Last author PMID 33042633 ↗

Grants 1

Operationalizing DNMT1-Targeting to Treat Chemorefractory Pancreatic Cancer R21CA263430 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Davendra P. S. Sohal · 1 shared paper, 2020 · strength 0.10
- Paper A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 i… PMID 33042633 ↗
Alok A. Khorana · 1 shared paper, 2020 · strength 0.10
- Paper A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 i… PMID 33042633 ↗
Terry H. Landowski · 1 shared paper, 2020 · strength 0.10
- Paper A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 i… PMID 33042633 ↗
Smitha Krishnamurthi · 1 shared paper, 2020 · strength 0.10
- Paper A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 i… PMID 33042633 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.